Skip to main content

Advertisement

SpringerLink
Log in

Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia

  • Case Report
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

To report the efficacy of combination photodynamic therapy and intravitreal ranibizumab for juxtafoveal, subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia (IMT).

Methods

A 56-year-old woman with visual loss due to SRNVM secondary to IMT underwent primary treatment with a combination of photodynamic therapy (PDT) and intravitreal ranibizumab (0.5 mg). PDT was done as per the TAP study protocol, except that the laser spot size was same as the greatest linear diameter (GLD) of the lesion. This was followed by intravitreal ranibizumab (0.5 mg), 2 days later.

Results

At the 16-week follow-up, clinical examination revealed regression of the SRNVM, with no evidence of subretinal fluid, exudates or fresh hemorrhages. Visual acuity improved by 2 Snellen lines (from 6/36 to 6/18). Clinical findings were confirmed on FFA and OCT. At the last follow-up at 9 months, the SRNVM remained quiescent and visual acuity stable. No treatment-related adverse effects were noted.

Conclusion

Combination therapy with PDT and intravitreal ranibizumab appears to be efficacious in the treatment of SRNVM associated with proliferative type 2 IMT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B (2006) Idiopathic macular telangiectasia. Arch Ophthalmol 124(4):450–460

    Article  PubMed  Google Scholar 

  2. Lee BL (1996) Bilateral subretinal neovascular membrane in idiopathic juxtafoveolar telangiectasis. Retina 16:344–346

    PubMed  CAS  Google Scholar 

  3. Berger AS, McCuen BW, Brown GC, Brownlow RL (1997) Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Retina 17:94–98

    Article  PubMed  CAS  Google Scholar 

  4. Potter MJ, Szabo SM, Sarraf D, Michels R, Schmidt-Erfurth U (2006) Photodynamic therapy for subretinal neovascularization in type 2A idiopathic juxtafoveolar telangiectasis. Can J Ophthalmol 41:34–37

    PubMed  Google Scholar 

  5. Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245:1045–1048

    Article  PubMed  CAS  Google Scholar 

  6. Ruys J, De Laey JJ, Vanderhaeghen Y, Van Aken EH (2007) Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane. Eye 21:1433–1434

    Article  PubMed  CAS  Google Scholar 

  7. Treatment of Age-related Macular Degeneration by Photodynamic therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age related macular degeneration with verteporfin. Arch Ophthalmol 117:1329–1345

    Google Scholar 

  8. Engelbrecht NE, Aaberg TM Jr, Sung J, Lewis ML (2002) Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis. Arch Ophthalmol 120:320–324

    PubMed  Google Scholar 

  9. Spaide RF (2006) Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 141(1):149–156

    Article  PubMed  Google Scholar 

  10. Shanmugam MP, Agarwal M (2005) RPE Atrophy following Photodynamic therapy in type 2A Idiopathic Parafoveal Telangiectasis. Indian J Ophthalmol 53:61–63

    Article  PubMed  Google Scholar 

  11. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A (2006) Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 26:988–993

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sankara Nethralaya, Medical Research Foundation, 18, College Road, 600006, Chennai, Tamil Nadu, India

    Pukhraj Rishi, Daraius Shroff & Ekta Rishi

Authors
  1. Pukhraj Rishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daraius Shroff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ekta Rishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pukhraj Rishi.

Additional information

The authors have full control of all primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data upon request. There are no funding or other conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rishi, P., Shroff, D. & Rishi, E. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol 246, 619–621 (2008). https://doi.org/10.1007/s00417-007-0732-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-007-0732-0

Keywords

Search

Navigation